Anas Younes, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, discusses future directions of lymphoma research at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. He speaks about ongoing research into biomarkers and precision medicine, highlighting that all lymphoma patients who give consent are being sequenced at the Memorial Sloan Kettering Cancer Center. Prof. Younes also discusses the potential of doublet or triplet combination therapies, as well as different types of immunotherapy.